| Literature DB >> 27550796 |
A Frisell1, J Lagergren2,3, J de Boniface4,5.
Abstract
BACKGROUND: Reconstructive alternatives should be discussed with women facing mastectomy for breast cancer. These include immediate and delayed reconstruction, which both have inherent advantages and disadvantages. Immediate reconstruction rates vary considerably in Swedish healthcare regions, and the aim of the study was to analyse reasons for this disparity.Entities:
Mesh:
Year: 2016 PMID: 27550796 PMCID: PMC5095775 DOI: 10.1002/bjs.10286
Source DB: PubMed Journal: Br J Surg ISSN: 0007-1323 Impact factor: 6.939
Patient and tumour characteristics for 2996 mastectomies (2929 women)
| No immediate reconstruction ( | Immediate reconstruction ( |
| |
|---|---|---|---|
| Age (years) | 66 (21–97) | 49 (21–80) | < 0·001 |
| Preoperative T category | < 0·001 | ||
| cTis ( | 97 (3·6) | 46 (17·0) | |
| cT1 (≤ 20 mm) | 988 (36·2) | 81 (30·0) | |
| cT2 (21–50 mm) | 1065 (39·1) | 67 (24·8) | |
| cT3 (> 50 mm) | 240 (8·8) | 21 (7·8) | |
| cT4 | 43 (1·6) | 3 (1·1) | |
| Missing or unknown | 293 (10·7) | 52 (19·3) | |
| Preoperative node status | < 0·001 | ||
| Negative | 2214 (81·2) | 250 (92·6) | |
| Positive | 484 (17·8) | 19 (7·0) | |
| Missing | 28 (1·0) | 1 (0·4) | |
| Postoperative invasive tumour size (mm) | 22 (1–150) | 17 (1–245) | < 0·001 |
| Postoperative node status | < 0·001 | ||
| Negative | 1478 (54·2) | 188 (69·6) | |
| Positive | 1096 (40·2) | 60 (22·2) | |
| Missing | 152 (5·6) | 22 (8·1) | |
| Histological subtype | 0·018 | ||
| Ductal | 1877 (68·9) | 151 (55·9) | |
| Lobular | 471 (17·3) | 17 (6·3) | |
| Other | 140 (5·1) | 7 (2·6) | |
| Missing | 238 (8·7) | 95 (35·2) | |
| Presence of multifocality | 674 (24·7) | 47 (17·4) | 0·858 |
| Nottingham histological grade | 0·131 | ||
| 1 | 361 (13·2) | 34 (12·6) | |
| 2 | 1323 (48·5) | 115 (42·6) | |
| 3 | 921 (33·8) | 106 (39·3) | |
| Missing | 121 (4·4) | 15 (5·6) | |
| Oestrogen receptor status | 0·406 | ||
| Positive | 2107 (77·3) | 165 (61·1) | |
| Negative | 390 (14·3) | 25 (9·3) | |
| Missing | 229 (8·4) | 80 (29·6) | |
| Progesterone receptor status | 0·093 | ||
| Positive | 1766 (64·8) | 143 (53·0) | |
| Negative | 719 (26·4) | 43 (15·9) | |
| Missing | 241 (8·8) | 84 (31·1) | |
| Her2/neu status | 0·915 | ||
| Positive | 392 (14·4) | 27 (10·0) | |
| Negative | 2064 (75·7) | 149 (55·2) | |
| Missing | 270 (9·9) | 94 (34·8) | |
| Proliferation (Ki‐67) | 24 (0–100) | 20 (0–95) | 0·019 |
Values in parentheses are percentages unless indicated otherwise:
values are median (range). One woman with no information on immediate reconstruction was excluded.
χ2 or Fisher's exact test, except
Mann–Whitney U test.
Immediate reconstruction rates and preoperative patient and tumour characteristics for 2996 mastectomies, in each Swedish healthcare region
| Swedish healthcare region | |||||||
|---|---|---|---|---|---|---|---|
| North ( | Stockholm/Gotland ( | South ( | South‐east ( | Uppsala/Örebro ( | West ( |
| |
| Immediate breast reconstruction rate | 10 (4·7) | 151 (26·4) | 30 (4·8) | 23 (6·1) | 39 (6·2) | 17 (3·0) | < 0·001 |
| Preoperative T category | < 0·001 | ||||||
| cT1 | 85 (39·9) | 145 (25·4) | 248 (39·4) | 138 (36·4) | 205 (32·5) | 248 (43·2) | |
| cT2 | 71 (33·3) | 227 (39·8) | 226 (35·9) | 127 (33·5) | 258 (41·0) | 223 (38·9) | |
| cT3 | 18 (8·5) | 72 (12·6) | 34 (5·4) | 33 (8·7) | 69 (11·0) | 35 (6·1) | |
| cT4 | 9 (4·2) | 11 (1·9) | 6 (1·0) | 4 (1·1) | 11 (1·7) | 5 (0·9) | |
|
| 8 (3·8) | 27 (4·7) | 49 (7·8) | 6 (1·6) | 25 (4·0) | 28 (4·9) | |
| Unknown or missing | 22 (10·3) | 89 (15·6) | 66 (10·5) | 71 (18·7) | 62 (9·8) | 35 (6·1) | |
| Preoperative N category | 0·082 | ||||||
| cN0 | 170 (79·8) | 480 (84·1) | 513 (81·6) | 316 (83·4) | 523 (83·0) | 462 (80·5) | |
| cN1 | 31 (14·6) | 84 (14·7) | 96 (15·3) | 60 (15·8) | 92 (14·6) | 106 (18·5) | |
| cN2 | 5 (2·3) | 3 (0·5) | 7 (1·1) | 0 (0) | 7 (1·1) | 1 (0·2) | |
| cN3 | 0 (0) | 2 (0·3) | 3 (0·5) | 0 (0) | 4 (0·6) | 2 (0·3) | |
| Missing | 7 (3·3) | 2 (0·3) | 10 (1·6) | 3 (0·8) | 4 (0·6) | 3 (0·5) | |
| Neoadjuvant therapy | 26 (12·2) | 94 (16·5) | 60 (9·5) | 41 (10·8) | 32 (5·1) | 26 (4·5) | < 0·001 |
| Postoperative radiotherapy planned | 91 (42·7) | 279 (48·9) | 201 (32·0) | 174 (45·9) | 274 (43·5) | 176 (30·7) | < 0·001 |
| Age at surgery (years) | 65 (28–93) | 62 (21–96) | 65 (26–94) | 63 (21–93) | 65 (24–94) | 66 (26–97) | 0·052 |
Values in parentheses are percentages unless indicated otherwise;
values are median (range) for individual patients per region.
Based on clinical examination and imaging modalities, following the TNM classification system.
Includes both endocrine and cytostatic treatments.
As recommended by the multidisciplinary team; includes both local and locoregional radiotherapy.
χ2 test, except
Kruskal–Wallis test.
Univariable and multivariable binary logistic regression analysis of factors, with performance of immediate breast reconstruction as the binary outcome effect measure
| Univariable analysis | Multivariable analysis | |||
|---|---|---|---|---|
| Hazard ratio |
| Hazard ratio |
| |
| Preoperative tumour size (TNM) | ||||
| cT1 (≤ 20 mm) | 1·00 (reference) | |||
| cT2 (21–50 mm) | 0·77 (0·55, 1·07) | 0·123 | 0·68 (0·41, 1·15) | 0·156 |
| cT3 (> 50 mm) | 1·07 (0·65, 1·76) | 0·802 | 1·01 (0·46, 2·19) | 0·983 |
| cT4 | 0·85 (0·26, 2·80) | 0·790 | 0·92 (0·08, 10·43) | 0·947 |
|
| 5·78 (3·81, 8·77) | < 0·001 | 3·21 (1·69, 6·10) | < 0·001 |
| Unknown primary | 2·22 (1·52, 3·24) | < 0·001 | 1·68 (0·95, 2·98) | 0·074 |
| Preoperative N category | ||||
| cN− | 1·00 (reference) | |||
| cN+ | 0·35 (0·22, 0·56) | < 0·001 | 0·31 (0·13, 0·73) | 0·007 |
| Age (years) | ||||
| < 41 | 1·00 (reference) | |||
| 41–50 | 0·82 (0·55, 1·21) | 0·322 | 0·93 (0·46, 1·88) | 0·848 |
| 51–60 | 0·50 (0·33, 0·75) | 0·001 | 0·58 (0·28, 1·17) | 0·129 |
| 61–70 | 0·13 (0·08, 0·22) | < 0·001 | 0·16 (0·07, 0·36) | < 0·001 |
| > 70 | 0·01 (0·01, 0·04) | < 0·001 | 0·02 (0·00, 0·08) | < 0·001 |
| Swedish healthcare region | ||||
| North | 1·00 (reference) | |||
| Stockholm/Gotland | 7·30 (3·77, 14·14) | < 0·001 | 4·91 (1·85, 13·06) | 0·001 |
| South | 1·02 (0·49, 2·13) | 0·954 | 1·07 (0·40, 2·88) | 0·885 |
| South‐east | 1·31 (0·61, 2·81) | 0·486 | 1·20 (0·42, 3·43) | 0·738 |
| Uppsala/Örebro | 1·34 (0·66, 2·73) | 0·421 | 1·05 (0·38, 2·95) | 0·919 |
| West | 0·62 (0·62, 1·38) | 0·239 | 0·60 (0·19, 1·90) | 0·381 |
| Neoadjuvant treatment | ||||
| No | 1·00 (reference) | |||
| Yes | 0·77 (0·48, 1·24) | 0·289 | 0·72 (0·30, 1·77) | 0·480 |
| Hereditary factors | ||||
| No | 1·00 (reference) | |||
| Yes | 1·35 (0·92, 1·99) | 0·121 | 1·33 (0·80, 2·22) | 0·274 |
| Patient participation in decision‐making regarding reconstruction | ||||
| Yes | 1·00 (reference) | |||
| No | 0·07 (0·04, 0·14) | < 0·001 | 0·41 (0·18, 0·90) | 0·026 |
| Patient informed about immediate reconstructive options | ||||
| Yes | 1·00 (reference) | |||
| No | 0·05 (0·25, 0·11) | < 0·001 | 0·10 (0·05, 0·21) | < 0·001 |
| In‐house plastic surgery services available at operating hospital | ||||
| Yes | 1·00 (reference) | |||
| No | 0·19 (0·13, 0·27) | < 0·001 | 0·39 (0·23, 0·66) | < 0·001 |
Values in parentheses are 95 per cent confidence intervals.
Preoperative patient‐reported perception of information about breast reconstruction and involvement in treatment decision, in each Swedish healthcare region
| Swedish healthcare region | |||||||
|---|---|---|---|---|---|---|---|
| North | Stockholm/Gotland | South | South‐east | Uppsala/Örebro | West |
| |
| Any age | |||||||
| Did you receive information about the possibility of immediate reconstruction of the breast? | |||||||
| Group 1 | 36 (45·6) | 123 (67·2) | 120 (48·4) | 64 (41·0) | 69 (35·8) | 63 (31·0) | <0·001 |
| Group 2 | 16 (25·0) | 130 (56·3) | 60 (27·8) | 43 (33·6) | 68 (26·4) | 53 (24·8) | <0·001 |
| Did you receive information about the possibility of delayed reconstruction of the breast in a second setting? | |||||||
| Group 1 | 47 (59·5) | 127 (67·9) | 160 (65·3) | 91 (57·6) | 122 (62·6) | 127 (62·6) | 0·008 |
| Group 2 | 33 (49·3) | 157 (67·7) | 120 (55·3) | 74 (57·4) | 135 (52·5) | 130 (60·7) | 0·425 |
| Did you feel involved in the decision‐making process whether or not to perform breast reconstruction? | |||||||
| Group 1 | 52 (72·2) | 136 (75·1) | 156 (66·1) | 88 (59·9) | 104 (58·1) | 114 (61·3) | 0·005 |
| Group 2 | 33 (53·2) | 164 (74·5) | 101 (50·0) | 61 (54·5) | 133 (59·1) | 108 (55·1) | <0·001 |
| Age up to 65 years | |||||||
| Did you receive information about the possibility of immediate reconstruction of the breast? | |||||||
| Group 1 | 28 (58·3) | 95 (83·3) | 84 (59·6) | 48 (56·5) | 55 (47·8) | 35 (34·3) | <0·001 |
| Group 2 | 12 (36·4) | 98 (73·7) | 40 (35·7) | 34 (42·5) | 45 (36·3) | 29 (27·1) | <0·001 |
| Did you receive information about the possibility of delayed reconstruction of the breast in a second setting? | |||||||
| Group 1 | 40 (83·3) | 97 (84·3) | 118 (84·9) | 70 (81·4) | 102 (87·2) | 85 (82·5) | 0·903 |
| Group 2 | 26 (74·3) | 119 (88·8) | 91 (81·3) | 66 (81·5) | 99 (80·5) | 88 (81·5) | 0·314 |
| Did you feel involved in the decision‐making process whether or not to perform breast reconstruction? | |||||||
| Group 1 | 36 (76·6) | 94 (83·9) | 100 (72·5) | 57 (68·7) | 78 (68·4) | 57 (62·6) | <0·001 |
| Group 2 | 17 (53·1) | 112 (85·5) | 58 (53·2) | 46 (62·2) | 81 (69·2) | 62 (61·4) | 0·018 |
Values are numbers of women who answered ‘Yes’ or ‘Yes, but not enough’ to each question, with percentages in parentheses. Group 1 (low tumour burden) consisted of women with clinically node‐negative cT1, cTis (in situ) or cT0 tumours. Group 2 (higher tumour burden) consisted of all remaining women.
χ2 test.